In re CPA Application of: Siani, M.A. et al. Serial No. of Prior Appln: 09/144,838

Atty Dkt. No.: GRFN-20/01US

Page 4

In The Specification:

Please rewrite the paragraph beginning at page 19, line 25 and continuing to page 20, line 9 as follows:

FS

Assays of particular interest employ receptors provided by tissues or cell preparations synthetic preparations and the like. Receptors of particular interest are lipid membrane-bound receptors generated by lipid matrix-assisted chemoselective chemical ligation as described in U.S. Patent Application Serial No. 144,964. Screening for binding of a cross-over protein ligand comprising one or more chromophores to a target receptor is preferably performed in a FRET assay. Ligand binding can be measured by any number of methods known in the art for FRET analyses, including steady state and time-resolved fluorescence by monitoring the change in fluorescence intensity, emission energy and/or anisotropy, for example, through energy transfer from a donor moiety to an acceptor moiety of the FRET system. (See, e.g., Wu et al., Analytical Biochem. (1994) 218: 1-13). FRET assays allow not only distance measurements, but also resolution of the range of donor- to-acceptor distances. FRET also can be used to show that the ligand and/or target receptor exists alternately in a single conformational state, or with a range of donor-to-acceptor distances when in a different state, such as when bound to a ligand. More than one donor-acceptor pairing may also be included.

Remarks

Claims 28-36 are presently pending; claims 1-27 and 37-51 have been withdrawn from consideration as directed to a non-elected invention..